Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Geographical Differences In Transfusion and Iron Chelation Practices In 1558 Patients with Transfusion-Dependent Anemias

Vip Viprakasit, MD, DPhil, Norbert Gattermann, MD, Jong Wook Lee, MD, John B. Porter, MD, Ali Taher, MD, Dany Habr, MD, Bernard Roubert, PhD, Gabor Domokos, PhD, Maria Domenica Cappellini, MD

Blood (2010) 116 (21): 4272.

https://doi.org/10.1182/blood.V116.21.4272.4272

Published: 2010

Journal Articles

Continued Improvement and Normalization of Myocardial T2* In Patients with β-thalassemia Major Treated with Deferasirox (Exjade®) for up to 3 Years

Dudley Pennell, MD, John B. Porter, MD, Maria Domenica Cappellini, MD, Lee Lee Chan, MD, Amal El-Beshlawy, MD, Yesim Aydinok, MD, Hishamshah Ibrahim, MD, Chi-Kong Li, MD, Vip Viprakasit, MD, DPhil, Mohsen Saleh Elalfy, MD, Antonis Kattamis, MD, Gillian Smith, MSc, Dany Habr, MD, Gabor Domokos, PhD, Bernard Roubert, PhD, Ali Taher, MD

Blood (2010) 116 (21): 4276.

https://doi.org/10.1182/blood.V116.21.4276.4276

Published: 2010

Journal Articles

Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial

Jong Wook Lee, Sung-Soo Yoon, Zhi Xiang Shen, Arnold Ganser, Hui-Chi Hsu, Dany Habr, Gabor Domokos, Bernard Roubert, John B. Porter, on behalf of the EPIC study investigators

Blood (2010) 116 (14): 2448–2454.

https://doi.org/10.1182/blood-2010-01-261289

Published: 2010

Journal Articles

Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia

Dudley J. Pennell, John B. Porter, Maria Domenica Cappellini, Amal El-Beshlawy, Lee Lee Chan, Yesim Aydinok, Mohsen Saleh Elalfy, Pranee Sutcharitchan, Chi-Kong Li, Hishamshah Ibrahim, Vip Viprakasit, Antonis Kattamis, Gillian Smith, Dany Habr, Gabor Domokos, Bernard Roubert, Ali Taher

Blood (2010) 115 (12): 2364–2371.

https://doi.org/10.1182/blood-2009-04-217455

Published: 2010

Journal Articles

Improved Patient Satisfaction, Adherence and Health-Related Quality of Life with Deferasirox (Exjade®) in β-Thalassemia Patients Previously Receiving Other Iron Chelation Therapies.

John B. Porter, Miranda Athanasiou-Metaxa, Donald K. Bowden, Jacques Troncy, Dany Habr, Gabor Domokos, Bernard Roubert, Diana Rofail, Adam Gater, Jean-François Baladi, M. Domenica Cappellini

Blood (2009) 114 (22): 2486.

https://doi.org/10.1182/blood.V114.22.2486.2486

Published: 2009

Journal Articles

Deferasirox (Exjade®) ≥30 Mg/Kg/Day Is Effective in Reducing Iron Burden in Thalassemia Major Patients Previously Chelated with Monotherapy or Combination Therapy.

Ali Taher, Mohsen Saleh Elalfy, Amal El-Beshlawy, Dunhua Zhou, Lee Lee Chan, Chi-Kong Li, Kai-Hsin Lin, John B. Porter, Pranee Sutcharitcharan, Dany Habr, Gabor Domokos, Bernard Roubert, M. Domenica Cappellini

Blood (2009) 114 (22): 4058.

https://doi.org/10.1182/blood.V114.22.4058.4058

Published: 2009

Journal Articles

Efficacy and Safety of Deferasirox (Exjade®) in β-Thalassemia Patients with Myocardial Siderosis: 2-Year Results From the EPIC Cardiac Sub-Study.

Dudley J. Pennell, John B. Porter, M. Domenica Cappellini, Lee Lee Chan, Amal El-Beshlawy, Yesim Aydinok, Hishamshah Ibrahim, Chi-Kong Li, Vip Viprakasit, Mohsen Saleh Elalfy, Antonis Kattamis, Gillian Smith, Dany Habr, Gabor Domokos, Bernard Roubert, Ali Taher

Blood (2009) 114 (22): 4062.

https://doi.org/10.1182/blood.V114.22.4062.4062

Published: 2009

Journal Articles

Correlation Between Decreased Serum Ferritin and Improved Liver Transaminases During Deferasirox (Exjade®) Treatment in Iron-Overloaded Patients with Myelodysplastic Syndromes.

Norbert Gattermann, Mathias Schmid, Agnès Guerci-Bresler, Matteo Della Porta, Kerry Taylor, Dany Habr, Gabor Domokos, Bernard Roubert, Pierre Fenaux

Blood (2009) 114 (22): 3803.

https://doi.org/10.1182/blood.V114.22.3803.3803

Published: 2009

Journal Articles

Deferasirox (Exjade®) Is Effective and Well Tolerated in Chelation-Naive and Previously Chelated Patients with Transfusion-Dependent Myelodysplastic Syndromes (MDS).

Mathias Schmid, Agnès Guerci-Bresler, Matteo Della Porta, Kerry Taylor, Dany Habr, Gabor Domokos, Bernard Roubert, Christian Rose, Norbert Gattermann, MD, PhD

Blood (2009) 114 (22): 3806.

https://doi.org/10.1182/blood.V114.22.3806.3806

Published: 2009

Journal Articles

Improvement in Right Ventricular Function Following 1 Year of Deferasirox Therapy in Patients with β-Thalassemia.

Gillian Smith, Dudley J. Pennell, John B. Porter, M. Domenica Cappellini, Lee Lee Chan, Amal El-Beshlawy, Yesim Aydinok, Hishamshah Ibrahim, Chi-Kong Lee, Vip Viprakasit, Mohsen Saleh Elalfy, Antonis Kattamis, Dany Habr, Gabor Domokos, Abdel Hmissi, Ali Taher

Blood (2009) 114 (22): 5106.

https://doi.org/10.1182/blood.V114.22.5106.5106

Published: 2009

Journal Articles

History of Hepatitis B or C Does Not Affect Safety and Efficacy of Deferasirox (Exjade®) in Thalassemia Major Patients: Sub-Analysis of the EPIC Trial.

M. Domenica Cappellini, Mohsen Saleh Elalfy, Amal El-Beshlawy, Antonis Kattamis, Lee Lee Chan, ChunFu Li, Kai-Hsin Lin, Giovanni Quarta, Pranee Sutcharitchan, Ali Taher, Dany Habr, Gabor Domokos, Bernard Roubert, John B. Porter

Blood (2009) 114 (22): 5107.

https://doi.org/10.1182/blood.V114.22.5107.5107

Published: 2009

Journal Articles

Efficacy and Safety of 1 Year’s Treatment with Deferasirox (Exjade ® ): Assessment of Regularly Transfused Patients with Diamond-Blackfan Anemia Enrolled in the EPIC Study.

John B Porter, Gian Luca Forni, Photis Beris, Ali Taher, Dany Habr, Gabor Domokos, Abdel Hmissi, Maria Domenica Cappellini

Blood (2008) 112 (11): 1048.

https://doi.org/10.1182/blood.V112.11.1048.1048

Published: 2008

Journal Articles

Satisfaction and Adherence Significantly Improves in Patients with β-Thalassemia and Myelodysplastic Syndromes Treated with Deferasirox (Exjade ® )

John B Porter, Donald Bowden, Arnold Ganser, Gabor Domokos, Diana Rofail, Jean-François Baladi, Maria Domenica Cappellini

Blood (2008) 112 (11): 1306.

https://doi.org/10.1182/blood.V112.11.1306.1306

Published: 2008

Journal Articles

Improved Health-Related Quality of Life in Patients with Hematological Disorders Receiving Deferasirox (Exjade ® )

John B Porter, Donald Bowden, Arnold Ganser, Gabor Domokos, Adam Gater, Jean-François Baladi, Maria Domenica Cappellini

Blood (2008) 112 (11): 1307.

https://doi.org/10.1182/blood.V112.11.1307.1307

Published: 2008

Journal Articles

Efficacy and Safety of Deferasirox (Exjade ® ) in Reducing Cardiac Iron in Patients with β-Thalassemia Major: Results from the Cardiac Substudy of the EPIC Trial

Dudley Pennell, John B Porter, Maria Domenica Cappellini, Chi-Kong Li, Yesim Aydinok, Chan Lee Lee, Antonis Kattamis, Gillian Smith, Dany Habr, Gabor Domokos, Abdel Hmissi, Ali Taher

Blood (2008) 112 (11): 3873.

https://doi.org/10.1182/blood.V112.11.3873.3873

Published: 2008

Journal Articles

Efficacy and Safety of Deferasirox (Exjade ® ) in Patients with Transfusion- Dependent Anemias: 1-Year Results from the Large, Prospective, Multicenter EPIC Study

Maria Domenica Cappellini, Amal El-Beshlawy, Antonis Kattamis, Jong Wook Lee, John F Seymour, Chi-Kong Li, Dany Habr, Gabor Domokos, Abdel Hmissi, Mohsen Saleh Elalfy

Blood (2008) 112 (11): 3875.

https://doi.org/10.1182/blood.V112.11.3875.3875

Published: 2008

Journal Articles

Efficacy and Safety of Once-Daily, Oral Iron Chelator Deferasirox (Exjade ® ) in a Large Group of Regularly Transfused Patients with β-Thalassemia Major

Maria Domenica Cappellini, Mohsen Saleh Elalfy, Antonis Kattamis, John F Seymour, Chan Lee Lee, John B Porter, Amal El-Beshlawy, Dany Habr, Gabor Domokos, Abdel Hmissi, Ali Taher

Blood (2008) 112 (11): 3878.

https://doi.org/10.1182/blood.V112.11.3878.3878

Published: 2008

Journal Articles

Transfusion History, Iron Chelation Practices and Status of Iron Overload across Various Transfusion-Dependent Anemias: Data from the Large- Scale, Prospective, 1-Year EPIC Trial

Maria Domenica Cappellini, Norbert Gattermann, Vip Viprakasit, Jong Wook Lee, John B Porter, Amal El-Beshlawy, Antonis Kattamis, John F Seymour, Chi-Kong Li, Dany Habr, Gabor Domokos, Abdel Hmissi, Mohsen Saleh Elalfy

Blood (2008) 112 (11): 3880.

https://doi.org/10.1182/blood.V112.11.3880.3880

Published: 2008

Journal Articles

Iron Chelation in Regularly Transfused Patients with Aplastic Anemia: Efficacy and Safety Results from the Large Deferasirox EPIC Trial

Jong Wook Lee, Sung-Soo Yoon, Zhi Xiang Shen, Hui-Chi Hsu, Arnold Ganser, Dany Habr, Gabor Domokos, Abdel Hmissi, John B Porter

Blood (2008) 112 (11): 439.

https://doi.org/10.1182/blood.V112.11.439.439

Published: 2008

Journal Articles

Effect of Deferasirox (Exjade ® ) on Labile Plasma Iron Levels in Heavily Iron-Overloaded Patients with Transfusion-Dependent Anemias Enrolled in the Large-Scale, Prospective 1-Year EPIC Trial

John B Porter, Maria Domenica Cappellini, Amal El-Beshlawy, Antonis Kattamis, John F Seymour, Jong Wook Lee, Hanspeter Nick, Dany Habr, Gabor Domokos, Abdel Hmissi, Ali Taher

Blood (2008) 112 (11): 3881.

https://doi.org/10.1182/blood.V112.11.3881.3881

Published: 2008

NARROW

Geographical Differences In Transfusion and Iron Chelation Practices In 1558 Patients with Transfusion-Dependent Anemias

Continued Improvement and Normalization of Myocardial T2* In Patients with β-thalassemia Major Treated with Deferasirox (Exjade®) for up to 3 Years

Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial

Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia

Improved Patient Satisfaction, Adherence and Health-Related Quality of Life with Deferasirox (Exjade®) in β-Thalassemia Patients Previously Receiving Other Iron Chelation Therapies.

Deferasirox (Exjade®) ≥30 Mg/Kg/Day Is Effective in Reducing Iron Burden in Thalassemia Major Patients Previously Chelated with Monotherapy or Combination Therapy.

Efficacy and Safety of Deferasirox (Exjade®) in β-Thalassemia Patients with Myocardial Siderosis: 2-Year Results From the EPIC Cardiac Sub-Study.

Correlation Between Decreased Serum Ferritin and Improved Liver Transaminases During Deferasirox (Exjade®) Treatment in Iron-Overloaded Patients with Myelodysplastic Syndromes.

Deferasirox (Exjade®) Is Effective and Well Tolerated in Chelation-Naive and Previously Chelated Patients with Transfusion-Dependent Myelodysplastic Syndromes (MDS).

Improvement in Right Ventricular Function Following 1 Year of Deferasirox Therapy in Patients with β-Thalassemia.

History of Hepatitis B or C Does Not Affect Safety and Efficacy of Deferasirox (Exjade®) in Thalassemia Major Patients: Sub-Analysis of the EPIC Trial.

Efficacy and Safety of 1 Year’s Treatment with Deferasirox (Exjade ® ): Assessment of Regularly Transfused Patients with Diamond-Blackfan Anemia Enrolled in the EPIC Study.

Satisfaction and Adherence Significantly Improves in Patients with β-Thalassemia and Myelodysplastic Syndromes Treated with Deferasirox (Exjade ® )

Improved Health-Related Quality of Life in Patients with Hematological Disorders Receiving Deferasirox (Exjade ® )

Efficacy and Safety of Deferasirox (Exjade ® ) in Reducing Cardiac Iron in Patients with β-Thalassemia Major: Results from the Cardiac Substudy of the EPIC Trial

Efficacy and Safety of Deferasirox (Exjade ® ) in Patients with Transfusion- Dependent Anemias: 1-Year Results from the Large, Prospective, Multicenter EPIC Study

Efficacy and Safety of Once-Daily, Oral Iron Chelator Deferasirox (Exjade ® ) in a Large Group of Regularly Transfused Patients with β-Thalassemia Major

Transfusion History, Iron Chelation Practices and Status of Iron Overload across Various Transfusion-Dependent Anemias: Data from the Large- Scale, Prospective, 1-Year EPIC Trial

Iron Chelation in Regularly Transfused Patients with Aplastic Anemia: Efficacy and Safety Results from the Large Deferasirox EPIC Trial

Effect of Deferasirox (Exjade ® ) on Labile Plasma Iron Levels in Heavily Iron-Overloaded Patients with Transfusion-Dependent Anemias Enrolled in the Large-Scale, Prospective 1-Year EPIC Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only